Ultragenyx Pharmaceutical (RARE) Capital Expenditures (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Capital Expenditures data on file, last reported at $1.0 million in Q1 2026.

• Quarterly Capital Expenditures changed 0.0% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.0 million (down 25.6% YoY) and the FY2025 annual result came in at $5.0 million, down 28.57% from the prior year.
• Capital Expenditures advanced to $1.0 million in Q1 2026 per RARE's latest filing, from -$62000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $36.6 million in Q3 2023 and bottomed at -$32.7 million in Q4 2023.
• The 5-year median for Capital Expenditures is $1.0 million (2025), against an average of $2.4 million.
• Peak annual rise in Capital Expenditures reached 1516.56% in 2023, while the deepest fall reached 1221.48% in 2023.
• Tracing RARE's Capital Expenditures over 5 years: stood at -$2.5 million in 2022, then tumbled by 1221.48% to -$32.7 million in 2023, then soared by 100.5% to $163000.0 in 2024, then plunged by 138.04% to -$62000.0 in 2025, then jumped by 1712.9% to $1.0 million in 2026.
• Per Business Quant, the three latest RARE Capital Expenditures figures stand at $1.0 million (Q1 2026), -$62000.0 (Q4 2025), and $1.3 million (Q3 2025).

Peer Comparison